EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

N/A

Manufactured by Gilead Sciences, Inc.

46,639 FDA adverse event reports analyzed

Last updated: 2026-04-14

About EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Gilead Sciences, Inc.. The most commonly reported adverse reactions for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE include BONE DENSITY DECREASED, CHRONIC KIDNEY DISEASE, BONE LOSS, OSTEONECROSIS, MULTIPLE FRACTURES. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE.

Top Adverse Reactions

BONE DENSITY DECREASED4,795 reports
CHRONIC KIDNEY DISEASE2,843 reports
BONE LOSS2,618 reports
OSTEONECROSIS2,592 reports
MULTIPLE FRACTURES2,424 reports
TOOTH LOSS2,284 reports
OSTEOPOROSIS2,254 reports
RENAL FAILURE2,219 reports
PAIN1,998 reports
EMOTIONAL DISTRESS1,913 reports
RENAL INJURY1,875 reports
ANXIETY1,768 reports
ANHEDONIA1,689 reports
SKELETAL INJURY1,621 reports
OSTEOPENIA1,488 reports
ACUTE KIDNEY INJURY635 reports
RENAL IMPAIRMENT621 reports
BLOOD CREATININE INCREASED593 reports
ECONOMIC PROBLEM590 reports
TOOTH INJURY367 reports
FRACTURE343 reports
VITAMIN D DEFICIENCY339 reports
BONE DENSITY ABNORMAL336 reports
DEPRESSION298 reports
NEPHROPATHY289 reports
FOOT FRACTURE278 reports
FATIGUE247 reports
BONE DEMINERALISATION238 reports
DEATH225 reports
ARTHRALGIA218 reports
NAUSEA207 reports
OSTEOARTHRITIS191 reports
GAIT DISTURBANCE165 reports
PRODUCT STORAGE ERROR162 reports
ANKLE FRACTURE157 reports
OFF LABEL USE153 reports
RIB FRACTURE153 reports
DIARRHOEA149 reports
TOOTH FRACTURE149 reports
HEADACHE145 reports
HIP FRACTURE145 reports
PRODUCT DOSE OMISSION ISSUE142 reports
DRUG INEFFECTIVE140 reports
WRIST FRACTURE140 reports
WEIGHT INCREASED132 reports
BONE DISORDER131 reports
ASTHENIA130 reports
BACK PAIN125 reports
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES125 reports
END STAGE RENAL DISEASE121 reports
HAND FRACTURE121 reports
PROTEINURIA119 reports
INSOMNIA111 reports
PROTEIN TOTAL ABNORMAL111 reports
HYPERTENSION108 reports
RASH108 reports
VOMITING103 reports
UPPER LIMB FRACTURE96 reports
HIP ARTHROPLASTY93 reports
LOWER LIMB FRACTURE93 reports
DIZZINESS91 reports
FOETAL EXPOSURE DURING PREGNANCY88 reports
NEPHROLITHIASIS87 reports
GLOMERULAR FILTRATION RATE DECREASED86 reports
ANAEMIA85 reports
RENAL DISORDER79 reports
BONE PAIN77 reports
PAIN IN EXTREMITY77 reports
INTERVERTEBRAL DISC DEGENERATION75 reports
MOBILITY DECREASED75 reports
WEIGHT DECREASED75 reports
FEMUR FRACTURE73 reports
SPINAL FRACTURE73 reports
FANCONI SYNDROME ACQUIRED68 reports
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME68 reports
PRODUCT DISPENSING ERROR66 reports
PRODUCT USE ISSUE66 reports
QUALITY OF LIFE DECREASED66 reports
MALAISE63 reports
BLOOD HIV RNA INCREASED62 reports
TIBIA FRACTURE62 reports
NEUROPATHY PERIPHERAL61 reports
SPINAL OSTEOARTHRITIS61 reports
DYSPNOEA60 reports
DYSSTASIA59 reports
PRURITUS59 reports
EXPOSURE DURING PREGNANCY58 reports
HOSPITALISATION57 reports
DENTAL CARIES55 reports
POLLAKIURIA55 reports
ARTHRITIS54 reports
DECREASED ACTIVITY54 reports
PROTEIN TOTAL INCREASED54 reports
PYREXIA54 reports
GLOMERULAR FILTRATION RATE ABNORMAL53 reports
OSTEOMALACIA53 reports
CONDITION AGGRAVATED52 reports
PARAESTHESIA52 reports
SPINAL COMPRESSION FRACTURE52 reports
FALL51 reports

Report Outcomes

Out of 11,008 classified reports for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE:

Serious 76.2%Non-Serious 23.8%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male7,935 (76.6%)
Female2,422 (23.4%)

Reports by Age

Age 53327 reports
Age 50286 reports
Age 55267 reports
Age 51255 reports
Age 54249 reports
Age 56243 reports
Age 57242 reports
Age 49240 reports
Age 52238 reports
Age 59236 reports
Age 47229 reports
Age 48225 reports
Age 58217 reports
Age 45198 reports
Age 60195 reports
Age 44187 reports
Age 46176 reports
Age 43168 reports
Age 40162 reports
Age 42162 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with EMTRICITABINE AND TENOFOVIR ALAFENAMIDE?

This profile reflects 46,639 FDA FAERS reports that mention EMTRICITABINE AND TENOFOVIR ALAFENAMIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE?

Frequently reported terms in FAERS include BONE DENSITY DECREASED, CHRONIC KIDNEY DISEASE, BONE LOSS, OSTEONECROSIS, MULTIPLE FRACTURES, TOOTH LOSS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures EMTRICITABINE AND TENOFOVIR ALAFENAMIDE?

Labeling and FAERS entries often list Gilead Sciences, Inc. in connection with EMTRICITABINE AND TENOFOVIR ALAFENAMIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.